Key result
Low-dose daunorubicin linked to fatal cardiogenic shock in a young female with AML.
Why the study?
Use of daunorubicin in acute myeloid leukaemia is limited by dose-dependent, late cardiac toxicity, but early severe cardiac damage after standard doses is not well described.
Can standard doses of daunorubicin cause early severe cardiac damage in patients with acute myeloid leukaemia?
Case Report (n=1)
Can standard doses of daunorubicin cause early severe cardiac damage in patients with acute myeloid leukaemia?
This case demonstrates that standard doses of daunorubicin can cause severe, early, and fatal cardiotoxicity in patients with acute myeloid leukaemia, even without prior cardiac history.
Raises caution for early daunorubicin cardiotoxicity in AML; hypothesis-generating and requires prospective validation before practice change.
Use of the anthracycline antibiotics daunorubicin and adriamycin as antineoplastic agents is limited by dose-dependent, late cardiac toxicity. We describe a patient who developed fatal cardiogenic shock after comparatively low dose daunorubicin early in the treatment of acute myeloid leukaemia (A.M.L.). She was young with no previous cardiac history: investigations for an infectious aetiology were negative and at post-mortem there was no evidence of leukaemic infiltration. This unusual case demonstrates that standard doses of daunorubicin in A.M.L. may be followed early in the treatment by severe cardiac damage.
No takes yet. Share an insight, caveat, or question.
Holyoake et al. (1991) conducted a case report in Acute Myeloid Leukaemia (n=1). Daunorubicin was evaluated on Fatal cardiogenic shock. A young female patient with acute myeloid leukaemia developed fatal cardiogenic shock early in treatment after receiving a comparatively low dose of daunorubicin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: